Related Experiment Videos
Update on fenofibrate
1University of Minnesota, College of Pharmacy, Weaver-Densford Hall 7 - 115C, 308 Harvard Street SE, Minneapolis, MN 55455, USA. guayx001@umn.edu.
Cardiovascular Drug Reviews
|December 14, 2002
Summary
Fenofibrate, a lipid-lowering drug, effectively reduces harmful cholesterol and triglycerides by activating PPAR-alpha. Early studies show promise in slowing atherosclerosis in type II diabetics.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Fenofibrate is a fibric acid derivative used to treat hyperlipidemia.
- Its active metabolite, fenofibric acid, modulates lipid profiles.
- It has been available since the 1970s, with US market entry in 1998.
Purpose of the Study:
- To summarize the pharmacodynamic effects and clinical utility of fenofibrate.
- To review its efficacy across various hyperlipidemia types.
- To discuss its safety profile and ongoing cardiovascular outcome trials.
Main Methods:
- Review of fenofibrate's mechanism of action via PPAR-alpha activation.
- Summary of clinical data on lipid-lowering effects.
- Analysis of safety data and outcomes from the DAIS trial.
Main Results:
- Fenofibrate reduces total cholesterol, LDL, triglycerides, and VLDL.
- It increases HDL and apolipoproteins AI and AII.
- The DAIS trial indicated slowed atherosclerotic progression in type II diabetics.
Conclusions:
- Fenofibrate demonstrates broad efficacy in managing diverse hyperlipidemias.
- It is generally well-tolerated with manageable side effects.
- Further outcome trials are anticipated to define its role in cardiovascular risk management.